One-year deal extension worth $3.2M to Trubion.

Wyeth Pharmaceuticals has decided to extend its research collaboration with Trubion Pharmaceuticals for an additional year. For these additional research services, Trubion will receive approximately $3.2 million.

The original agreement between the two companies was inked in December 2005 for the development and worldwide commercialization of TRU-015, Trubion’s lead product that is currently in Phase II development for the treatment of rheumatoid arthritis, and other CD20-directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20.

Related Links:

Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting

Previous articleU of Michigan Study Details How Lack of CHFR Sets Stage for Breast Cancer
Next articleGSK Makes Cancer Cell Genomic Data Available on caBIG